Introduction: More Options, More Decisions

The treatment algorithm for hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer has grown substantially more complex over the past several years. What once followed a predictable linear sequence (aromatase inhibitor, fulvestrant, then chemotherapy) has expanded in multiple directions at once. Novel oral endocrine agents are entering the clinic, molecular testing meaningfully informs treatment selection, and antibody-drug conjugates are moving earlier in the metastatic sequence. The challenge now is less about having enough options and more about knowing when and how to deploy each one.

New Endocrine Agents: The Next Generation After Aromatase Inhibitors

Aromatase inhibitors remain foundational, but their tolerability limitations are clinically underappreciated. The 4.4% discontinuation rate commonly cited in trials substantially underestimates real-world rates in the adjuvant setting, which approaches 12% in 2 years in observational data. Hot flashes, joint stiffness, and vaginal dryness affect adherence in ways that don't always surface in randomized trial reporting. 

Several novel selective estrogen receptor degraders (SERDs) and related drugs are entering or advancing through clinical development with the goal of replacing current endocrine therapeutic options on the basis of better tolerability and activity. Many novel SERDs, most notably camizestrant, carry an unusual toxicity profile: bradycardia and photopsias (visual flashing lights, particularly noticeable in dim environments). The bradycardia can produce remarkably low resting heart rates in otherwise healthy older patients. Capturing the frequency and characteristics of photopsias requires active probing: patients often attribute them to imagination and won't volunteer the symptom unprompted. "Did you see flashing lights when you woke up to use the bathroom last night?" is the kind of question that can bring to surface this side effect.

In the adjuvant setting, multiple clinical trials are ongoing investigating novel SERDs in various iterations. The Novera study is currently evaluating a novel SERD, giredestrant, specifically in patients who have failed or not tolerated aromatase inhibitors. in the metastatic setting, the evERA trial and several phase 2 studies have shown that combining a SERD with a second agent, rather than using it as monotherapy, produces more meaningful PFS prolongation, suggesting that the next step for SERDs may be rational combinations rather than single-agent use.

The Metastatic Treatment Framework: Two Strategic Modes

Metastatic HR+/HER2- breast cancer is a vastly heterogeneous disease with diverse evolutionary patterns. It can have an indolent natural history whereby patients enjoy long remissions with each line of therapy, while in others breast cancer may progress rapidly through each line of therapy leading to progressively shorter intervals of remission and rapid transition to chemotherapy and antibody drug conjugates.

Accordingly, for a patient with slow-growing bone-only disease, endocrine therapy with or without a CDK4/6 inhibitor may be the optimal long-term approach. For a patient with a rapidly progressive visceral metastatic disease, symptomatic metastases, and altogether clear clinical need for rapid response, an antibody-drug conjugate or chemotherapy may be more appropriate even early in the metastatic course. Predicting the natural history of metastatic breast cancer and, accordingly, choosing the right therapy that balances efficacy against toxicity is not straightforward and relies heavily on clinical judgment. 

First-line therapy: Endocrine therapy with or without a CDK4/6 inhibitor is the standard. CDK4/6 inhibitors are not mandatory in every situation; for patients with indolent disease and patients living in remote settings where frequent CBC monitoring is impractical, endocrine therapy alone remains a reasonable starting approach. Sequencing therapies following progression on aromatase inhibitor plus CDK4/6 inhibitor and the role of newer agents like elacestrant (approved for ESR1-mutated disease after prior CDK4/6 inhibitor) are now important clinical decisions.

ESR1 Mutations: Emergence Under Therapeutic Pressure and Implications

 

Under therapeutic pressure from aromatase inhibitors and CDK4/6 inhibitors, estrogen receptor (ESR1) mutations emerge. The emergence of this mutation is not invariably associated with clinical and/or radiographic progression. The estrogen receptor (ER) is a transcription factor. It is now known that when it mutates, it binds to transcription start sites where the wildtype estrogen receptor does not bind. The constitutive and ligand-independent activity of the mutated receptor, altered chromatin accessibility, and action of additional transcription factors lead to a self-perpetuating cycle of tumor growth that does not require estrogens and is indifferent to the ER. The transition from an estrogen-dependent/ER-dependent state to either an estrogen-independent/ER-dependent state or an estrogen-independent/ER-independent (or ER-indifferent) state is not clinically evident.

In practice, the detection of ESR1 mutation in circulating tumor DNA does not portend that the patient will respond to a novel SERD with activity against the mutated ER. In many patients, the window of opportunity for intervention may precede clinical and/or radiographic progression. Nonetheless, monitoring for the emergence of ESR1 mutation by means of circulating tumor DNA, and even moreso, changing treatment on the basis of this emergence in the absence of clinical and/or radiographic progression, remains a controversial approach. The crux of this controversy is the unknown long-term benefit of this early switch strategy.

Novel Targeted Therapies in Development

The recent success of the CDK4/6 inhibitors (re)opened the door to a broader wave of cell cycle and signaling inhibitors now in clinical development: CDK2 inhibitors, CDK7 inhibitors, novel PI3K inhibitors, and CDK4-selective agents. Each addresses a specific node in the resistance landscape. The pipeline is deep, and several of these agents are already in phase 2 and phase 3 trials, with some expected to reach FDA consideration within the next two to three years.

Capivasertib remains the established option for PIK3CA-mutated metastatic disease in patients who have received prior CDK4/6 inhibitor therapy. Alpelisib, the predecessor FDA approved agent for PIK3CA mutated metastatic HR+/HER2- breast cancer, remains an option though its toxicity profile (rash, diarrhea, and especially hyperglycemia) requires careful patient selection and monitoring.

Antibody-Drug Conjugates: Understanding Why Toxicity Is Unavoidable

ADCs have transformed the treatment landscape of all breast cancer subtypes, but their mechanism of action creates an inherent toxicity challenge. Out of every hundred ADC molecules administered, only one or two reach the tumor. The remaining 98-99% of the ADC molecules are cleared by normal tissues, producing on- or off-target off-tumor toxicities that cannot be fully eliminated by improving targeting. This is not a failure of drug design; it is a structural feature of the ADC class. Understanding this limitation helps set appropriate patient expectations and informs toxicity management strategies.

For Patients

If you have been diagnosed with hormone receptor-positive breast cancer that has spread, the treatment options available today are substantially more varied and more effective than they were even five years ago. Oral targeted medications can control disease in many patients for years with manageable side effects. If you are on endocrine therapy and develop new symptoms, even subtle ones like back pain or new joint discomfort, discuss them with your oncologist promptly, as such symptoms may reflect disease changes and can inform important treatment decisions. 

Key Takeaways

  • Even though the mutated estrogen receptor mediates endocrine resistance and accelerates the transition to chemotherapy, monitoring for the emergence of ESR1 mutation and switching treatment upon its detection remains controversial as the long term benefits of this approach are unknown.

  • CDK4/6 inhibitors are standard first-line but not mandatory option in every patient; patients with indolent metastatic disease and monitoring challenges may reasonably start on endocrine therapy alone.

  • .Metastatic HR+/Her2- breast cancer has a highly variable natural history. Predicting the natural history of this disease and aligning treatment options accordingly currently relies heavily on medical judgment. 

  • Despite the targeted nature of the ADCs, toxicities are inherent to this class of drugs as the majority of ADC disposition occurs in normal tissues.

References

  1. evERA trial Mayer E, et al. Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the Phase III evERA BC trial. Presented at: ESMO Congress; 2025 October 17-21; Berlin, Germany. LBA #16..

  2. EMERALD trial. Elacestrant vs endocrine therapy in ESR1-mutated metastatic breast cancer. Journal of Clinical Oncology, 2023.

  3. Vaklavas C. "Hormone Receptor Positive Breast Cancer." Presented at the 2026 Alaska Hematology Oncology Conference, Anchorage, AK, May 2026.